Vortioxetine for Cognitive Impairment in Major Depressive Disorder During Post-COVID Syndrome: Real-World Evidence.

IF 4.5 2区医学 Q1 PSYCHIATRY

Journal of Clinical Psychiatry Pub Date : 2025-05-05 DOI:10.4088/JCP.24m15387

Hernan F Guillen-Burgos, Juan F Galvez-Florez, Sergio Moreno-López, Juan-Manuel Anaya, Angela T H Kwan, Roger S McIntyre

{"title":"Vortioxetine for Cognitive Impairment in Major Depressive Disorder During Post-COVID Syndrome: Real-World Evidence.","authors":"Hernan F Guillen-Burgos, Juan F Galvez-Florez, Sergio Moreno-López, Juan-Manuel Anaya, Angela T H Kwan, Roger S McIntyre","doi":"10.4088/JCP.24m15387","DOIUrl":null,"url":null,"abstract":"Objective: To compare the effectiveness of vortioxetine versus escitalopram and sertraline as a treatment in individuals with major depressive disorder (MDD) and post-COVID syndrome (PCS).Methods: This is a prospective, open-label, comparative effectiveness study in individuals with new-onset MDD as PCS outcome. The study was carried out in 1 clinical site. Individuals who had a history of confirmed SARS-CoV 2 infection, who met World Health Organization-defined criteria for PCS, and who met new-onset of MDD criteria according to DSM-5-TR were included. Participants that were eligible were assigned to receive vortioxetine at 10-20 mg/d, escitalopram 10-20 mg/d, or sertraline 50-200 mg/d over 8 weeks. The primary and secondary outcomes were changes from baseline to end point in Digital Symbol Substitution Test (DSST) and Montgomery-Asberg Depression Rating Scale (MADRS) or Patient Reported Outcome Measurement Information System Fatigue Short Form 7a (PROMIS 7a), respectively. Data were collected during January 2022 and December 2023.Results: 140 participants were assigned to received vortioxetine (n = 70), escitalopram (n = 36), or sertraline (n = 34). Participants assigned to vortioxetine exhibited significant changes in DSST scores from baseline to end point compared to escitalopram or sertraline (least squares [LS] mean differences, 8.25; 95% CI, 6.25-10.25; P < .001; LS mean differences, 8.00; 95% CI, 5.95-10.06; P < .001, respectively). Participants in the vortioxetine treatment group reported significantly greater changes in total MADRS scores from baseline to end point compared to escitalopram or sertraline (LS mean differences, -4.06; 95% CI, -4.92 to -3.20; P < .001; LS mean differences, -3.94; 95% CI, -4.83 to -3.06; P < .001, respectively).Conclusion: Vortioxetine has a significant procognitive effect. Antidepressant effects and improvement in fatigue symptoms (PROMIS 7a) also were observed.","PeriodicalId":50234,"journal":{"name":"Journal of Clinical Psychiatry","volume":"86 2","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4088/JCP.24m15387","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To compare the effectiveness of vortioxetine versus escitalopram and sertraline as a treatment in individuals with major depressive disorder (MDD) and post-COVID syndrome (PCS).

Methods: This is a prospective, open-label, comparative effectiveness study in individuals with new-onset MDD as PCS outcome. The study was carried out in 1 clinical site. Individuals who had a history of confirmed SARS-CoV 2 infection, who met World Health Organization-defined criteria for PCS, and who met new-onset of MDD criteria according to DSM-5-TR were included. Participants that were eligible were assigned to receive vortioxetine at 10-20 mg/d, escitalopram 10-20 mg/d, or sertraline 50-200 mg/d over 8 weeks. The primary and secondary outcomes were changes from baseline to end point in Digital Symbol Substitution Test (DSST) and Montgomery-Asberg Depression Rating Scale (MADRS) or Patient Reported Outcome Measurement Information System Fatigue Short Form 7a (PROMIS 7a), respectively. Data were collected during January 2022 and December 2023.

Results: 140 participants were assigned to received vortioxetine (n = 70), escitalopram (n = 36), or sertraline (n = 34). Participants assigned to vortioxetine exhibited significant changes in DSST scores from baseline to end point compared to escitalopram or sertraline (least squares [LS] mean differences, 8.25; 95% CI, 6.25-10.25; P < .001; LS mean differences, 8.00; 95% CI, 5.95-10.06; P < .001, respectively). Participants in the vortioxetine treatment group reported significantly greater changes in total MADRS scores from baseline to end point compared to escitalopram or sertraline (LS mean differences, -4.06; 95% CI, -4.92 to -3.20; P < .001; LS mean differences, -3.94; 95% CI, -4.83 to -3.06; P < .001, respectively).

Conclusion: Vortioxetine has a significant procognitive effect. Antidepressant effects and improvement in fatigue symptoms (PROMIS 7a) also were observed.

查看原文本刊更多论文

沃替西汀对covid后综合征期间重度抑郁症认知障碍的治疗：现实世界证据

目的：比较沃替西汀与艾司西酞普兰和舍曲林治疗重度抑郁症（MDD）和covid后综合征（PCS）的疗效。方法：这是一项前瞻性、开放标签、比较有效性的研究，以新发重度抑郁症作为PCS结果。本研究在1个临床地点进行。包括有确诊的SARS-CoV 2感染史、符合世界卫生组织定义的PCS标准以及符合DSM-5-TR中新发重度抑郁症标准的个体。符合条件的参与者被分配接受沃替西汀10- 20mg /d，艾司西酞普兰10- 20mg /d，或舍曲林50- 200mg /d，持续8周。主要和次要结局分别为数字符号替代测试（DSST）和Montgomery-Asberg抑郁评定量表（MADRS）或患者报告结果测量信息系统疲劳短表7a （PROMIS 7a）从基线到终点的变化。数据收集于2022年1月至2023年12月。结果：140名参与者被分配接受vortioxetine (n = 70), escitalopram （n = 36）或舍曲林（n = 34）。与艾司西酞普兰或舍曲林相比，沃替西汀组的受试者从基线到终点的DSST评分有显著变化(最小二乘[LS]平均差值为8.25；95% ci, 6.25-10.25；P < .001；LS平均差值为8.00；95% ci, 5.95-10.06；P < 0.001)。与艾司西酞普兰或舍曲林相比，沃替西汀治疗组的参与者报告的MADRS总评分从基线到终点的变化显著更大(LS平均差异，-4.06；95% CI, -4.92 ~ -3.20；P < .001；LS平均差值为-3.94；95% CI, -4.83 ~ -3.06；P < 0.001)。结论：沃替西汀具有显著的促进认知作用。抗抑郁药的作用和疲劳症状的改善（PROMIS 7a）也被观察到。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Psychiatry 医学-精神病学

CiteScore

7.40

自引率

1.90%

发文量

审稿时长

3-8 weeks

期刊介绍： For over 75 years, The Journal of Clinical Psychiatry has been a leading source of peer-reviewed articles offering the latest information on mental health topics to psychiatrists and other medical professionals.The Journal of Clinical Psychiatry is the leading psychiatric resource for clinical information and covers disorders including depression, bipolar disorder, schizophrenia, anxiety, addiction, posttraumatic stress disorder, and attention-deficit/hyperactivity disorder while exploring the newest advances in diagnosis and treatment.